David Lebowitz
Stock Analyst at Citigroup
(3.57)
# 938
Out of 4,944 analysts
114
Total ratings
56.63%
Success rate
3.26%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $191.15 | +51.71% | 14 | Aug 8, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $80 → $77 | $36.88 | +108.79% | 3 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $85.85 | +19.98% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $41.27 | -7.92% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $11.98 | +83.64% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $50.38 | +32.99% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $38.49 | +45.49% | 3 | May 15, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $14 → $10 | $11.00 | -9.09% | 8 | May 9, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.60 | -6.25% | 6 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $43.10 | +48.49% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $48.17 | -6.58% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $65.14 | +4.39% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $24.99 | +180.11% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $19.84 | +86.49% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $373.46 | +2.29% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $58.30 | +64.67% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $3.22 | +272.67% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $432.52 | -62.08% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $15.63 | +149.52% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $13.45 | +56.13% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $4.45 | +9,001.12% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.09 | +1,184.40% | 2 | Oct 12, 2021 |
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $191.15
Upside: +51.71%
Cytokinetics
Aug 8, 2025
Maintains: Buy
Price Target: $80 → $77
Current: $36.88
Upside: +108.79%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $85.85
Upside: +19.98%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $41.27
Upside: -7.92%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $11.98
Upside: +83.64%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $50.38
Upside: +32.99%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $38.49
Upside: +45.49%
Intellia Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $11.00
Upside: -9.09%
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.60
Upside: -6.25%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $43.10
Upside: +48.49%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $48.17
Upside: -6.58%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $65.14
Upside: +4.39%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $24.99
Upside: +180.11%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $19.84
Upside: +86.49%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $373.46
Upside: +2.29%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $58.30
Upside: +64.67%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $3.22
Upside: +272.67%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $432.52
Upside: -62.08%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $15.63
Upside: +149.52%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $13.45
Upside: +56.13%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $4.45
Upside: +9,001.12%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.09
Upside: +1,184.40%